American Association for Cancer Research
15357163mct171156-sup-192801_2_supp_4632383_p5zjq3.pdf (53.32 MB)

Supplementary Tables S1-S3; Supplementary Figures S1-S6 including legends; and Supplementary References from A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition

Download (53.32 MB)
journal contribution
posted on 2023-04-03, 15:23 authored by Anika Trenner, Julia Godau, Alessandro A. Sartori

Table S1: Primary antibodies; Table S2: Secondary antibodies; Table S3: siRNA oligos; Figure S1, related to Figure 1: BRC4 peptide inhibits RAD51 binding to BRCA2 and RAD51 self-oligomerization; Figure S2; related to Figure 2: Efficient cellular uptake of TAMRA- and Fluorescein-labeled R9-BRC4 peptides; Figure S3, related to Figure 4: BRC4 peptide suppresses DNA damage-induced RAD51 foci formation in U2OS cells; Figure S4, related to Figure 5: BRC4 peptide does not affect bulk DNA replication; Figure S5, related to Figure 6: BRC4 peptide confers DNA damage hypersensitivity; Figure S6, related to Figure 6: BRC4 peptide confers olaparib hypersensitivity in cancer cell lines.


Krebsliga Schweiz

Swiss National Science Foundation

Promedica Stiftung

Novartis Foundation for Medical-Biological Research



Under conditions of genotoxic stress, cancer cells strongly rely on efficient DNA repair to survive and proliferate. The human BRCA2 tumor suppressor protein is indispensable for the repair of DNA double-strand breaks by homologous recombination (HR) by virtue of its ability to promote RAD51 loading onto single-stranded DNA. Therefore, blocking the interaction between BRCA2 and RAD51 could significantly improve the efficacy of conventional anticancer therapies. However, targeting protein–protein interaction (PPI) interfaces has proven challenging because flat and large PPI surfaces generally do not support binding of small-molecule inhibitors. In contrast, peptides are more potent for targeting PPIs but are otherwise difficult to deliver into cells. Here, we report that a synthetic 16-mer peptide derived from the BRC4 repeat motif of BRCA2 is capable of blocking RAD51 binding to BRCA2. Efficient noncytotoxic cellular uptake of a nona-arginine (R9)-conjugated version of the BRC4 peptide interferes with DNA damage–induced RAD51 foci formation and HR. Moreover, transduction of the BRC4 peptide impairs replication fork–protective function of BRCA2 and triggers MRE11-dependent degradation of nascent DNA in response to DNA replication stress. Finally, the BRC4 cell-penetrating peptide (CPP) confers selective hypersensitivity to PARP inhibition in cancer cells but spares noncancerous cells. Taken together, our data highlight an innovative approach to develop novel peptide-based DNA repair inhibitors and establish BRCA2-derived CPPs as promising anticancer agents. Mol Cancer Ther; 17(7); 1392–404. ©2018 AACR.